Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Ampm Research Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,049,116

467 payments

Through program year 2022, Ampm Research Clinic is reported as receiving $1,049,116 in research payments, across 467 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $34,898 13
2021 Research $267,869 66
2020 Research $132,648 40
2019 Research $613,701 348

Breakdown

Who paid Research payments · program years 2019–2022
  1. Akebia Therapeutics Inc $383,282 351 payments
  2. AstraZeneca Pharmaceuticals LP $364,630 3 payments
  3. GlaxoSmithKline, LLC. $114,461 58 payments
  4. EMD Serono, Inc. $73,777 3 payments
  5. OPKO Pharmaceuticals, LLC $58,000 34 payments
  6. Novartis Pharmaceuticals Corporation $27,621 6 payments
  7. Novo Nordisk AS $17,493 1 payment
  8. United Therapeutics Corporation $7,352 10 payments
  9. Merck Sharp & Dohme Corporation $2,500 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. A Phase 3 Multicenter Randomised Open Label Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients $209,950 1 payment
  2. Akb-6548-Ci-0017 $177,859 306 payments
  3. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $146,667 1 payment
  4. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $114,461 58 payments
  5. Akb-6548-Ci-0017 $108,013 1 payment
  6. A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. $73,777 3 payments
  7. Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI $58,000 34 payments
  8. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate-Conversion) $53,416 9 payments
  9. A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma $25,100 2 payments
  10. Cor-001-02 $17,493 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record